4.5 Review

RNA (Epi)genetics in cardiovascular diseases

期刊

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.yjmcc.2015.07.012

关键词

MicroRNAs; Long non-coding RNAs; Cardiovascular diseases; RNA therapeutics

资金

  1. Italian Ministry of Health [GR2010_2302354]
  2. Marie Curie Action [PIRG08-GA-2010-276993]
  3. Italian Association for Cancer Research (AIRC) [15801]
  4. Italian Ministry of Education, University and Research (MIUR) [2010RNXM9C]
  5. Advanced Grant (CardioEpigen) from the European Research Council (ERC) [294609]
  6. European Research Council (ERC) [294609] Funding Source: European Research Council (ERC)

向作者/读者索取更多资源

Next-generation sequencing has greatly improved our knowledge of the mammalian transcriptome, identifying thousands of non-coding RNAs (ncRNAs), which are RNAs that rather than translate for proteins, have regulatory functions. Perhaps unsurprisingly, dysregulation of individual ncRNAs has been associated with the development of pathologies, including of the cardiovascular system. The best-characterized group of ncRNAs is represented by the short, highly conserved RNAs named microRNAs (miRNAs). This ncRNA species, which principally exerts an inhibitory action on gene expression, has been implicated in many cardiovascular diseases. Unfortunately, the complexity of action of other types of ncRNA, such as long ncRNAs, has somewhat hampered the study of their role in cardiovascular pathologies. A detailed characterization of the mechanism of action of these different ncRNA species would be conducive to a better understanding of the cellular processes underlying cardiovascular disease and may lead to the development of innovative therapeutic strategies. Here, we give an overview of the current knowledge on the function of ncRNAs and their roles in cardiovascular disease development, concentrating mainly on microRNAs and long ncRNAs. (c) 2015 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据